Ronald J. A. Wanders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ronald J. A. Wanders has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Lodewijk Ijlst
Clinical Biochemistry and 5 Paediatrics Academic Medical Netherlands Centre University of Amsterdam
4 shared publicationsEwald H. Hettema
University of Amsterdam, Academic Medical Centre, Departments of Clinical Chemistry,1 Biochemistry,2 and Paediatrics,3 Emma Children's Hospital, 1100 DE Amsterdam, The Netherlands
3 shared publicationsHenk F. Tabak
University of Amsterdam, Academic Medical Centre, Departments of Clinical Chemistry,1 Biochemistry,2 and Paediatrics,3 Emma Children's Hospital, 1100 DE Amsterdam, The Netherlands
3 shared publicationsRob Ofman
Clinical Chemistry Laboratory for Genetic Metabolic Diseases (Room F0-224) PO Box 22700 1100 DE Amsterdam The Netherlands
3 shared publicationsS. Denis
Departments of 1Clinical Chemistry and 2Pediatrics, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam; and 3Department of Pathology, Albert Einstein College of Medicine, Bronx, NY
3 shared publicationsC.W.T. van Roermund
Departments of 1Clinical Chemistry and 2Pediatrics, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam; and 3Department of Pathology, Albert Einstein College of Medicine, Bronx, NY
2 shared publications
Latest Publications
- 1 June 2002
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 70 (6) , 1589-1593
Reinvestigation of Peroxisomal 3-Ketoacyl-CoA Thiolase Deficiency: Identification of the True Defect at the Level of d-Bifunctional Protein
- 1 June 2002
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 70 (6) , 1589-1593
Reinvestigation of Peroxisomal 3-Ketoacyl-CoA Thiolase Deficiency: Identification of the True Defect at the Level of d-Bifunctional Protein
- Open Access
- 1 July 2001
- Published by Oxford University Press (OUP) in Brain
- Vol. 124 (7) , 1426-1437
Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome
Sjögren–Larsson syndrome (SLS) is an autosomal recessively inherited neurocutaneous disorder caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH). We report the clinical characteristics and the results of molecular studies in 19 SLS patients. Patients 1–17 show the classical triad of severe clinical abnormalities including ichthyosis, mental retardation and spasticity. Most patients were born preterm, and all patients exhibit ocular abnormalities and pruritus. Electro-encephalography shows a slow background activity, without other abnormalities. MRI of the brain shows an arrest of myelination, periventricular signal abnormalities of white matter and mild ventricular enlargement. Cerebral 1H-MR spectroscopy reveals a characteristic, abnormal lipid peak. The degree of white matter abnormality in the MRIs and the height of the lipid peak in 1H-MR spectra do not correlate with the severity of the neurological signs. The clinical presentation and the clinical course is strikingly similar in these patients. Patient 18 shows a mild phenotype that essentially contains the same, but less severe, clinical features. Patient 19 exhibits the typical, but very mild, dermatological and ocular abnormalities, without any clinical neurological involvement. The diagnosis of SLS was confirmed by demonstration of the enzyme defect in cultured skin fibroblasts. Furthermore, as might be predicted from the essential role of FALDH in leucotriene B4 (LTB4) metabolism, elevated urinary concentrations of LTB4 and 20-OH-LTB4 were found in all patients studied. Molecular studies of the FALDH gene revealed eight different mutations, including three new ones: a large 26-base pair deletion (21–46del), a missense mutation (80C→T) and an insertion mutation (487–488insA). The vast majority of SLS patients seem to be severely affected independent of their genotype.
- 1 July 2001
- Published by Oxford University Press (OUP) in Brain
- Vol. 124 (7) , 1426-1437
Open AccessClinical, biochemical and molecular genetic characteristics of 19 patients with the Sjogren-Larsson syndrome
Sjögren–Larsson syndrome (SLS) is an autosomal recessively inherited neurocutaneous disorder caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH). We report the clinical characteristics and the results of molecular studies in 19 SLS patients. Patients 1–17 show the classical triad of severe clinical abnormalities including ichthyosis, mental retardation and spasticity. Most patients were born preterm, and all patients exhibit ocular abnormalities and pruritus. Electro-encephalography shows a slow background activity, without other abnormalities. MRI of the brain shows an arrest of myelination, periventricular signal abnormalities of white matter and mild ventricular enlargement. Cerebral 1H-MR spectroscopy reveals a characteristic, abnormal lipid peak. The degree of white matter abnormality in the MRIs and the height of the lipid peak in 1H-MR spectra do not correlate with the severity of the neurological signs. The clinical presentation and the clinical course is strikingly similar in these patients. Patient 18 shows a mild phenotype that essentially contains the same, but less severe, clinical features. Patient 19 exhibits the typical, but very mild, dermatological and ocular abnormalities, without any clinical neurological involvement. The diagnosis of SLS was confirmed by demonstration of the enzyme defect in cultured skin fibroblasts. Furthermore, as might be predicted from the essential role of FALDH in leucotriene B4 (LTB4) metabolism, elevated urinary concentrations of LTB4 and 20-OH-LTB4 were found in all patients studied. Molecular studies of the FALDH gene revealed eight different mutations, including three new ones: a large 26-base pair deletion (21–46del), a missense mutation (80C→T) and an insertion mutation (487–488insA). The vast majority of SLS patients seem to be severely affected independent of their genotype.
- Open Access
- 1 July 2001
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 21 (13) , 4321-4329
Identification of a Peroxisomal ATP Carrier Required for Medium-Chain Fatty Acid β-Oxidation and Normal Peroxisome Proliferation in Saccharomyces cerevisiae
We have characterized the role of YPR128cp, the orthologue of human PMP34, in fatty acid metabolism and peroxisomal proliferation inSaccharomyces cerevisiae. YPR128cp belongs to the mitochondrial carrier family (MCF) of solute transporters and is localized in the peroxisomal membrane. Disruption of theYPR128c gene results in impaired growth of the yeast with the medium-chain fatty acid (MCFA) laurate as a single carbon source, whereas normal growth was observed with the long-chain fatty acid (LCFA) oleate. MCFA but not LCFA β-oxidation activity was markedly reduced in intact ypr128cΔ mutant cells compared to intact wild-type cells, but comparable activities were found in the corresponding lysates. These results imply that a transport step specific for MCFA β-oxidation is impaired in ypr128cΔ cells. Since MCFA β-oxidation in peroxisomes requires both ATP and CoASH for activation of the MCFAs into their corresponding coenzyme A esters, we studied whether YPR128cp is an ATP carrier. For this purpose we have used firefly luciferase targeted to peroxisomes to measure ATP consumption inside peroxisomes. We show that peroxisomal luciferase activity was strongly reduced in intact ypr128cΔ mutant cells compared to wild-type cells but comparable in lysates of both cell strains. We conclude that YPR128cp most likely mediates the transport of ATP across the peroxisomal membrane.
- 1 July 2001
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 21 (13) , 4321-4329
Open AccessIdentification of a Peroxisomal ATP Carrier Required for Medium-Chain Fatty Acid β-Oxidation and Normal Peroxisome Proliferation in Saccharomyces cerevisiae
We have characterized the role of YPR128cp, the orthologue of human PMP34, in fatty acid metabolism and peroxisomal proliferation inSaccharomyces cerevisiae. YPR128cp belongs to the mitochondrial carrier family (MCF) of solute transporters and is localized in the peroxisomal membrane. Disruption of theYPR128c gene results in impaired growth of the yeast with the medium-chain fatty acid (MCFA) laurate as a single carbon source, whereas normal growth was observed with the long-chain fatty acid (LCFA) oleate. MCFA but not LCFA β-oxidation activity was markedly reduced in intact ypr128cΔ mutant cells compared to intact wild-type cells, but comparable activities were found in the corresponding lysates. These results imply that a transport step specific for MCFA β-oxidation is impaired in ypr128cΔ cells. Since MCFA β-oxidation in peroxisomes requires both ATP and CoASH for activation of the MCFAs into their corresponding coenzyme A esters, we studied whether YPR128cp is an ATP carrier. For this purpose we have used firefly luciferase targeted to peroxisomes to measure ATP consumption inside peroxisomes. We show that peroxisomal luciferase activity was strongly reduced in intact ypr128cΔ mutant cells compared to wild-type cells but comparable in lysates of both cell strains. We conclude that YPR128cp most likely mediates the transport of ATP across the peroxisomal membrane.
- 1 April 2001
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 29 (2) , 250-67
Peroxisomal fatty acid α- and β-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases
Peroxisomes are subcellular organelles with an indispensable role in cellular metabolism. The importance of peroxisomes for humans is stressed by the existence of a group of genetic diseases in humans in which there is an impairment in one or more peroxisomal functions. Most of these functions have to do with lipid metabolism including the alpha- and beta-oxidation of fatty acids. Here we describe the current state of knowledge about peroxisomal fatty acid alpha- and beta-oxidation with particular emphasis on the following: (1) the substrates beta-oxidized in peroxisomes; (2) the enzymology of the alpha- and beta-oxidation systems; (3) the permeability properties of the peroxisomal membrane and the role of the different transporters therein; (4) the interaction with other subcellular compartments, including the mitochondria, which are the ultimate site of NADH re-oxidation and full degradation of acetyl-CoA to CO(2) and water; and (5) the different disorders of peroxisomal alpha- and beta-oxidation.
- 1 April 2001
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 29 (2) , 250-67
Peroxisomal fatty acid α- and β-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases
Peroxisomes are subcellular organelles with an indispensable role in cellular metabolism. The importance of peroxisomes for humans is stressed by the existence of a group of genetic diseases in humans in which there is an impairment in one or more peroxisomal functions. Most of these functions have to do with lipid metabolism including the alpha- and beta-oxidation of fatty acids. Here we describe the current state of knowledge about peroxisomal fatty acid alpha- and beta-oxidation with particular emphasis on the following: (1) the substrates beta-oxidized in peroxisomes; (2) the enzymology of the alpha- and beta-oxidation systems; (3) the permeability properties of the peroxisomal membrane and the role of the different transporters therein; (4) the interaction with other subcellular compartments, including the mitochondria, which are the ultimate site of NADH re-oxidation and full degradation of acetyl-CoA to CO(2) and water; and (5) the different disorders of peroxisomal alpha- and beta-oxidation.
- Open Access
- 1 May 2000
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 9 (8) , 1195-1200
Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease
Refsum’s disease (RD) is an inherited neurological syndrome biochemically characterized by the accumulation of phytanic acid in plasma and tissues. Patients with RD are unable to degrade phytanic acid due to a deficient activity of phytanoyl-CoA hydroxylase (PhyH), a peroxisomal enzyme catalysing the first step of phytanic acid α-oxidation. To enable mutation analysis of RD at the genome level, we have elucidated the genomic organization of the PHYH gene. The gene is ~21 kb and contains nine exons and eight introns. Mutation analysis of PHYH cDNA from 22 patients with RD revealed 14 different missense mutations, a 3 bp insertion, and a 1 bp deletion, which were all confirmed at the genome level. A 111 bp deletion identified in the PHYH cDNA of several patients with RD was due to either one of two different mutations in the same splice acceptor site, which result in skipping of exon 3. Six mutations, including a large in-frame deletion and five missense mutations, were expressed in the yeast Saccharomyces cerevisiae to study their effect on PhyH activity. The results showed that all these mutations lead to an enzymatically inactive PhyH protein.
- 1 May 2000
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 9 (8) , 1195-1200
Open AccessHuman phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease
Refsum’s disease (RD) is an inherited neurological syndrome biochemically characterized by the accumulation of phytanic acid in plasma and tissues. Patients with RD are unable to degrade phytanic acid due to a deficient activity of phytanoyl-CoA hydroxylase (PhyH), a peroxisomal enzyme catalysing the first step of phytanic acid α-oxidation. To enable mutation analysis of RD at the genome level, we have elucidated the genomic organization of the PHYH gene. The gene is ~21 kb and contains nine exons and eight introns. Mutation analysis of PHYH cDNA from 22 patients with RD revealed 14 different missense mutations, a 3 bp insertion, and a 1 bp deletion, which were all confirmed at the genome level. A 111 bp deletion identified in the PHYH cDNA of several patients with RD was due to either one of two different mutations in the same splice acceptor site, which result in skipping of exon 3. Six mutations, including a large in-frame deletion and five missense mutations, were expressed in the yeast Saccharomyces cerevisiae to study their effect on PhyH activity. The results showed that all these mutations lead to an enzymatically inactive PhyH protein.
- 1 January 2000
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 32 (1-3) , 89-106
Peroxisomes, Lipid Metabolism, and Human Disease
In the past few years, much has been learned about the metabolic functions of peroxisomes. These studies have shown that peroxisomes play a major role in lipid metabolism, including fatty acid...
- 1 January 2000
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 32 (1-3) , 89-106
Peroxisomes, Lipid Metabolism, and Human Disease
In the past few years, much has been learned about the metabolic functions of peroxisomes. These studies have shown that peroxisomes play a major role in lipid metabolism, including fatty acid...
- Open Access
- 1 August 1999
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 8 (8) , 1509-1516
Enoyl-CoA Hydratase Deficiency: Identification of a New Type of D-Bifunctional Protein Deficiency
D-bifunctional protein is involved in the peroxisomal β-oxidation of very long chain fatty acids, branched chain fatty acids and bile acid intermediates. In line with the central role of D-bifunctional protein in the β-oxidation of these three types of fatty acids, all patients with D-bifunctional protein deficiency so far reported in the literature show elevated levels of very long chain fatty acids, branched chain fatty acids and bile acid intermediates. In contrast, we now report two novel patients with D-bifunctional protein deficiency who both have normal levels of bile acid intermediates. Complementation analysis and D-bifunctional protein activity measurements revealed that both patients had an isolated defect in the enoyl-CoA hydratase domain of D-bifunctional protein. Subsequent mutation analysis showed that both patients are homozygous for a missense mutation (N457Y), which is located in the enoyl-CoA hydratase coding part of the D-bifunctional protein gene. Expression of the mutant protein in the yeast Saccharomyces cerevisiae confirmed that the N457Y mutation s the disease-causing mutation. Immunoblot analysis of patient fibroblast homogenates showed that the protein levels of full-length D-bifunctional protein were strongly reduced while the enoyl-CoA hydratase component produced after processing within the peroxisome was undetectable, which indicates that the mutation leads to an unstable protein.
- 1 August 1999
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 8 (8) , 1509-1516
Open AccessEnoyl-CoA Hydratase Deficiency: Identification of a New Type of D-Bifunctional Protein Deficiency
D-bifunctional protein is involved in the peroxisomal β-oxidation of very long chain fatty acids, branched chain fatty acids and bile acid intermediates. In line with the central role of D-bifunctional protein in the β-oxidation of these three types of fatty acids, all patients with D-bifunctional protein deficiency so far reported in the literature show elevated levels of very long chain fatty acids, branched chain fatty acids and bile acid intermediates. In contrast, we now report two novel patients with D-bifunctional protein deficiency who both have normal levels of bile acid intermediates. Complementation analysis and D-bifunctional protein activity measurements revealed that both patients had an isolated defect in the enoyl-CoA hydratase domain of D-bifunctional protein. Subsequent mutation analysis showed that both patients are homozygous for a missense mutation (N457Y), which is located in the enoyl-CoA hydratase coding part of the D-bifunctional protein gene. Expression of the mutant protein in the yeast Saccharomyces cerevisiae confirmed that the N457Y mutation s the disease-causing mutation. Immunoblot analysis of patient fibroblast homogenates showed that the protein levels of full-length D-bifunctional protein were strongly reduced while the enoyl-CoA hydratase component produced after processing within the peroxisome was undetectable, which indicates that the mutation leads to an unstable protein.
- 1 June 1999
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 22 (4) , 442-487
Disorders of mitochondrial fatty acyl‐CoA β‐oxidation
In recent years tremendous progress has been made with respect to the enzymology of the mitochondrial fatty acid β‐oxidation machinery and defects therein. Firstly, a number of new mitochondrial β‐oxidation enzymes have been identified, including very‐long‐chain acyl‐CoA dehydrogenase (VLCAD) and mitochondrial trifunctional protein (MTP). Secondly, the introduction of tandem MS for the analysis of plasma acylcarnitines has greatly facilitated the identification of patients with a defect in fatty acid oxidation (FAO). These two developments explain why the number of defined FAO disorders has increased dramatically, making FAO disorders the most rapidly growing group of inborn errors of metabolism. In this review we describe the current state of knowledge of the enzymes involved in the mitochondrial oxidation of straight‐chain, branched‐chain and (poly)unsaturated fatty acyl‐CoAs as well as disorders of fatty acid oxidation. The laboratory diagnosis of these disorders is described, with particular emphasis on the methods used to identify the underlying enzyme defect and the molecular mutations. In addition, a simple flowchart is presented as a guide to the identification of mitochondrial FAO‐disorders. Finally, treatment strategies are discussed briefly.
- 1 June 1999
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 22 (4) , 442-487
Disorders of mitochondrial fatty acyl‐CoA β‐oxidation
In recent years tremendous progress has been made with respect to the enzymology of the mitochondrial fatty acid β‐oxidation machinery and defects therein. Firstly, a number of new mitochondrial β‐oxidation enzymes have been identified, including very‐long‐chain acyl‐CoA dehydrogenase (VLCAD) and mitochondrial trifunctional protein (MTP). Secondly, the introduction of tandem MS for the analysis of plasma acylcarnitines has greatly facilitated the identification of patients with a defect in fatty acid oxidation (FAO). These two developments explain why the number of defined FAO disorders has increased dramatically, making FAO disorders the most rapidly growing group of inborn errors of metabolism. In this review we describe the current state of knowledge of the enzymes involved in the mitochondrial oxidation of straight‐chain, branched‐chain and (poly)unsaturated fatty acyl‐CoAs as well as disorders of fatty acid oxidation. The laboratory diagnosis of these disorders is described, with particular emphasis on the methods used to identify the underlying enzyme defect and the molecular mutations. In addition, a simple flowchart is presented as a guide to the identification of mitochondrial FAO‐disorders. Finally, treatment strategies are discussed briefly.
- 1 April 1999
- Published by Springer Nature in Neurochemical Research
- Vol. 24 (4) , 565-580
Peroxisomal Disorders: Clinical, Biochemical, and Molecular Aspects
Peroxisomes are subcellular organelles catalyzing a number of indispensable functions in cellular metabolism. The importance of peroxisomes in man is stressed by the existence of an expanding group...
- 1 April 1999
- Published by Springer Nature in Neurochemical Research
- Vol. 24 (4) , 565-580
Peroxisomal Disorders: Clinical, Biochemical, and Molecular Aspects
Peroxisomes are subcellular organelles catalyzing a number of indispensable functions in cellular metabolism. The importance of peroxisomes in man is stressed by the existence of an expanding group...